Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma

被引：3
|
作者：
Ghatalia, Pooja [1 ]
Plimack, Elizabeth R. [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA 19111 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2023年 / 20卷 / 12期
关键词：
CISPLATIN; CHEMOTHERAPY; CANCER; UNFIT;
D O I：
10.1038/s41571-023-00814-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Following the recent FDA Accelerated Approval of enfortumab vedotin (EV) plus pembrolizumab for patients with advanced-stage urothelial carcinoma who are cisplatin-ineligible, herein we highlight key clinical outcomes with this combination based on results from Cohort K of the pivotal phase Ib/II EV-103 trial. We also discuss treatment sequencing, de-escalation strategies and toxicity management as EV-pembrolizumab becomes widely used in clinical practice.
引用
收藏
页码：818 / 819
页数：2
相关论文
共 50 条
  • [1] Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    Li, Shan
    Yuan, Dan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [2] Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Powles, T.
    Valderrama, B. P.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano, D.
    Fornarini, G.
    Li, J. R.
    Guemues, M.
    Mar, N.
    Loriot, Y.
    Flechon, A.
    Duran, I
    Drakaki, A.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10) : 875 - 888
  • [3] Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma
    Santoni, Matteo
    Rizzo, Alessandro
    Massari, Francesco
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2025,
  • [4] Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer
    Sternschuss, Michal
    Rosenberg, Jonathan E.
    FUTURE ONCOLOGY, 2025, : 1333 - 1348
  • [5] Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
    Bantounou, Maria A.
    Plascevic, Josip
    MacDonald, Lewis
    Wong, Man Chun
    O'Connell, Neasa
    Galley, Helen F.
    CURRENT UROLOGY, 2023, 17 (04) : 271 - 279
  • [6] Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
    Furubayashi, Nobuki
    Negishi, Takahito
    Mochida, Manabu
    Kijima, Atsuhiro
    Katsuki, Harumichi
    Nakamura, Motonobu
    IN VIVO, 2025, 39 (01): : 411 - 418
  • [7] Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma
    Nakagawa, Ryunosuke
    Izumi, Kouji
    Toriumi, Ren
    Aoyama, Shuhei
    Kano, Hiroshi
    Makino, Tomoyuki
    Naito, Renato
    Kadomoto, Suguru
    Iwamoto, Hiroaki
    Yaegashi, Hiroshi
    Kawaguchi, Shohei
    Nohara, Takahiro
    Shigehara, Kazuyoshi
    Mizokami, Atsushi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (03) : 524 - 531
  • [8] Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt, Joaquim
    Nadal, Rosa
    MED, 2024, 5 (06): : 490 - 492
  • [9] Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract
    Chan, Kok Hoe
    Shu, Tung
    Al Shaarani, Majd
    Cen, Putao
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2024, 12
  • [10] Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma
    Minami, Keita
    Narimatsu, Rei
    Sasaki, Hajime
    Tanabe, Tatsu
    Tanaka, Hiroshi
    IJU CASE REPORTS, 2025, 8 (03) : 257 - 260
12345